You are here: All Products  > Insilico Out-Licenses Global Rights for USP1 Inhibitor to Exelixis for $80 Million Upfront

Insilico Out-Licenses Global Rights for USP1 Inhibitor to Exelixis for $80 Million Upfront

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products